Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tim Delahaye"'
Autor:
Jonatan Dewulf, Tal Flieswasser, Tim Delahaye, Christel Vangestel, Alan Miranda, Hans de Haard, Julie Jacobs, Evelien Smits, Tim Van den Wyngaert, Filipe Elvas
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-15 (2023)
Abstract Background CD70-CD27 is a costimulatory ligand-receptor pair in the tumor necrosis factor receptor family. With only limited expression in normal tissues, CD70 is constitutively expressed in a variety of solid tumors and hematologic malignan
Externí odkaz:
https://doaj.org/article/527f1504ab2342e59911d47fa04d8a86
Autor:
Astrid De Meulenaere, Tijl Vermassen, David Creytens, Stijn De Keukeleire, Tim Delahaye, Philippe Deron, Fréderic Duprez, Samson Fung, Patrick Pauwels, Liesbeth Ferdinande, Sylvie Rottey
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2300-2313 (2021)
Abstract CD70 is expressed in up to 80% of nasopharyngeal carcinoma (NPC) cases. Cusatuzumab is a humanized anti‐CD70 monoclonal antibody, with dual action mechanisms: induction of cytotoxicity against CD70+ tumor cells and reduction in CD70‐CD27
Externí odkaz:
https://doaj.org/article/d937f00205db456b849d7045bb391b76
Autor:
Clare I Campbell, Rhona McGonigal, Jennifer A Barrie, Jolien Delaere, Laura Bracke, Madeleine E Cunningham, Denggao Yao, Tim Delahaye, Inge Van de Walle, Hugh J Willison
Publikováno v:
Brain communications. 4(6)
The involvement of the complement pathway in Guillain–Barré syndrome pathogenesis has been demonstrated in both patient biosamples and animal models. One proposed mechanism is that anti-ganglioside antibodies mediate neural membrane injury through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b460b05b6bf3c63d9dcaa3de6ae3a934
https://pubmed.ncbi.nlm.nih.gov/36523267
https://pubmed.ncbi.nlm.nih.gov/36523267
Autor:
Adrian F. Ochsenbein, Ulrike Bacher, Hans de Haard, Ellen Erzeel, David Francisco, Anna Hultberg, Samson Fung, Magdalena Hinterbrandner, Markus G. Manz, Yara Banz, Mahan Moshir, Thomas Pabst, Tim Delahaye, Luc Van Rompaey, Sabine Höpner, Rouven Müller, Carsten Riether, Domenica Gandini, Walid H. Gharib, Rémy Bruggmann, Nicolas Leupin
Acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs) that resist conventional chemotherapy and are the major cause of relapse1,2. Hypomethylating agents (HMAs) are the standard of care in the treatment of older or unfit patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69bd75a7a31c6457437ffc638a812048
https://www.zora.uzh.ch/id/eprint/190892/
https://www.zora.uzh.ch/id/eprint/190892/
Autor:
Walid H. Gharib, Rouven Müller, Samson Fung, Mahan Moshir, Tim Delahaye, Yara Banz, Hans de Haard, Thomas Pabst, Rémy Bruggmann, Adrian F. Ochsenbein, Ellen Erzeel, Luc Van Rompaey, Sabine Höpner, Markus G. Manz, Carsten Riether, David Francisco, Nicolas Leupin, Domenica Gandini, Vera Ulrike Bacher, Magdalena Hinterbrandner, Anna Hultberg
Publikováno v:
Blood. 134:234-234
Introduction Acute myeloid leukemia (AML) is a heterogenous hematological malignancy driven by leukemia stem cells (LSCs) (Lapidot et al, 1994). LSCs resistant against conventional chemotherapy represent the major cause of relapse. Elderly or unfit A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c21c9955c103117af4c57763baaeade8
https://doi.org/10.1182/blood-2019-129916
https://doi.org/10.1182/blood-2019-129916
Autor:
Stefano Pileri, Karen Zwaenepoel, Koen De Winnie, Armand Bensussan, Marie Maerevoet, Maxime Battistella, Helene Moins, Jean-Marie Michot, Martine Bagot, Luc Van Rompaey, Patrick Pauwels, Valentina Tabanelli, Teresa Marafioti, Marie Beylot-Barry, Tim Delahaye, Franck Morschhauser, Fritz Offner, Domenica Gandini, Angelica Calleri, Nicolas Leupin, Anna Hultberg, Federica Melle, Stéphane Dalle, Pier Luigi Zinzani, Giovanna Motta, Mahan Moshir, Hans de Haard, Jean-Michel Cayuela, Piotr Zabrocki, Anne Marie-Cardine, Vincent Ribrag, Karen Silence
Publikováno v:
Blood. 132:1627-1627
Introduction Cutaneous T-cell lymphoma (CTCL), a heterogeneous group of rare non-Hodgkin's lymphomas, is characterized by infiltration of malignant clonally expanded T lymphocytes in the skin and is very challenging to treat at advanced stages. Aroun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::293b062d162f8d1c46fa4c7ebef0ffa5
https://doi.org/10.1182/blood-2018-99-118204
https://doi.org/10.1182/blood-2018-99-118204
Autor:
Yara Banz, Samson Fung, Markus G. Manz, Carsten Riether, Sabine Höpner, Hans de Haard, Tim Delahaye, Anna Hultberg, Thomas Pabst, Adrian F. Ochsenbein, Domenica Gandini, Mahan Moshir, Rouven Müller, Luc Van Rompaey, Ulrike Bacher, Ellen Erzeel, Mario Bargetzi, Magdalena Hinterbrandner, Nicolas Leupin
Publikováno v:
Blood. 132:2680-2680
Outcomes in elderly patients with acute myeloid leukemia (AML) are still adverse, as the majority does not qualify for intensive therapy or allogenic stem cell transplantation (ASCT). DNA hypomethylating agents (HMAs) induce remissions and prolong su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f176cb04e8afee899b2ed239a594bb0
https://doi.org/10.1182/blood-2018-99-118302
https://doi.org/10.1182/blood-2018-99-118302